Unexpected mortality reduction with abciximab for in-stent restenosis

Journal of Invasive Cardiology

Volumn 12, Issue 11, 2000, Pages 540-544

  Mukherjee, Debabrata ^a   Reginelli, Joel P ^a   Moliterno, David J ^a   Yadav, Jay S ^a   Schneider, Jakob P ^a   Raymond, Russell ^a   Whitlow, Patrick L ^a   Franco, Irving ^a   Topol, Eric J ^a   Ellis, Stephen G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Abciximab; Coronary intervention; GP IIb IIIa inhibitors; Restenosis

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ARTICLE; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; RETROSPECTIVE STUDY; STENT; SURVIVAL RATE; TIME;

ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECURRENCE; RETROSPECTIVE STUDIES; STENTS; SURVIVAL RATE; TIME FACTORS;

EID: 0034322375     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Mintz GS, Hoffmann R, Mehran R, et al. In-stent restenosis: The Washington Hospital Center experience. Am J Cardiol 1998;81:7E-13E.
2. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med 1994;330:956-961.
3. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta 3 blockade with percutaneous coronary intervention. EPIC (Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complications) investigator group. JAMA 1997;278:479-484.
4. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. The EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for STENTing) investigators. Lancet 1998;352:87-92.
5. Baim DS, Levine MJ, Leon MB, et al. Management of restenosis within the Palmaz-Schatz coronary stent (the U.S. multi-center experience). The U.S. Palmaz-Schatz stent investigators. Am J Cardiol 1993;71:364-366.
6. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
7. The PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
8. The PRISM-PLUS (Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms) study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
9. Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-928.
10. Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT study. Circulation 1999;100:2477-2484.
11. Coller BS. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-2380.
12. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
13. Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J 1996;17:9-18.
14. Anderson K, Ferguson JI, Stoner G, Weisman H. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention (PCI). Circulation 1997;97(Suppl I):I-162.
15. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicenter randomized trial. EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. Presented at the American Heart Association, 71st Annual Scientific Sessions, Dallas, Texas, 1998. Lancet 1999;354:2019-2024.
16. Cannon CP. Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: Unstable angina/non-ST segment elevation myocardial infarction. Clin Cardiol 1999;22:1V-30-IV-36.
17. Coller BS. Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J 1999;138:S1-S5.
18. 3 integrins. Circulation 1998;98:1085-1091.
19. Neumann FJ, Zohlnhofer D, Fakhoury L, et al. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999;34:1420-1426.
20. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000;101:252-257.
21. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg cohort study, 1984 to 1992. Circulation 1999;99:237-242.
22. Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med 2000;45:391-418.
23. Jager A, van Hinsbergh VW, Kostense PJ, et al. Von Willebrand factor, c-reactive protein, and 5-year mortality in diabetic and non-diabetic subjects: The Hoorn study. Arterioscler Thromb Vasc Biol 1999;19:3071-3078.
24. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of c-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-1521.
25. Lee SG, Lee CW, Hong MK, et al. Predictors of diffuse-type in-stent restenosis after coronary stent implantation. Cathet Cardiovasc Intervent 1999;47:406-409.
26. Sakamoto T, Kawarabayashi T, Taguchi H, et al. Intravascular ultrasound-guided balloon angioplasty for treatment of instent restenosis. Cathet Cardiovasc Intervent 1999;47:298-303.